Search results
This guideline aims at providing criteria to select medicinal products for which active surveillance for collecting post-authorisation data in pregnancy is necessary. It provides guidance on how to monitor accidental or intended exposure to medicinal products during pregnancy and specific requirements for
Scientific guidelines. This document describes how to assess the risk of an adverse reproductive/developmental effect in human based on reproductive toxicity studies in animals and human clinical data.
The European Medicines Agency's (EMA) provides answers to frequently asked questions on good manufacturing practice (GMP) and good distribution practice (GDP), as discussed and agreed by the GMP/GDP Inspectors Working Group.
1 lut 2019 · Oral mifepristone (Mifeprex), 200 mg, followed 24 hours later by misoprostol, 800 mcg vaginally, is the most effective regimen for medical management of early pregnancy loss and, when available,...
Another algorithm prospectively identifies codes for gestational age using the US-specific ICD-10-CM coding system in US health claims (Identification of pregnancies and infants within a US commercial healthcare administrative claims database, Pharmacoepidemiol Drug Saf. 2022 May 27).
16 mar 2023 · Vaginal spotting or bleeding occurs in approximately 25 percent of pregnancies in the first trimester (up to 13+6 weeks [ie, 13 weeks plus 6 days of gestation]) [1]. It is much less common in the second trimester (14+0 to 27+6 weeks), occurring in one to two percent of pregnancies [2].
1 lut 2019 · Approximately one-fourth of pregnant women will experience bleeding in the first trimester. The differential diagnosis includes threatened abortion, early pregnancy loss, and ectopic pregnancy. Pain and heavy bleeding are associated with an increased risk of early pregnancy loss.
